Moderna Inc (WBO:MRNA)
€ 38.03 -0.48 (-1.25%) Market Cap: 14.61 Bil Enterprise Value: 9.32 Bil PE Ratio: 0 PB Ratio: 1.30 GF Score: 53/100

Moderna Inc at Goldman Sachs Healthcare CEOs Unscripted Conference: A View from the Top (Virtual) Transcript

Jan 06, 2022 / 07:00PM GMT
Release Date Price: €191.2 (-4.17%)
Salveen Jaswal Richter
Goldman Sachs Group, Inc., Research Division - VP

Good afternoon. Thank you for joining us for the Goldman Sachs CEO Unscripted Conference. We're really pleased to have Stephane Bancel, CEO of Moderna. To start off, Stephane, thank you for joining us, and happy new year. To start off here, Moderna has announced in vitro data suggesting that the current COVID-19 vaccine formulation has good potential for cross protection against Omicron. Could you provide an overview of what we know thus far about Omicron and Spikevax's ability to address this variant?

Questions & Answers

Stephane Bancel
Moderna, Inc. - CEO & Director

Sure. So good afternoon. Happy new year, Salveen, and thank you so much for having us today. So as we've shared publicly, very similar to other vaccines, given the big genetic drift between the Wuhan strain and the Omicron strain, as anticipated, when we just saw the sequence on Thanksgiving weekend. We're seeing a very material drop of neutralizing antibody post the second dose. The great news is that with

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot